New HTA Methodology Could Solve Value Conundrum
Executive Summary
A new methodology for evaluating the benefits of new medicines aims to make funding decisions more transparent and structured. It could also offer an alternative to the way health technology appraisals reflect value.
You may also be interested in...
UK’s NICE Aims To Knock Firms’ Health Economic Models Into Shape
The scientific advice department at UK HTA body NICE is offering a new peer-review service to companies that want to make sure their economic models are as watertight as possible for making submissions to health technology assessment agencies and payers. One pilot project has already taken place.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.